Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech giant CSL (CSL) completes its $750 million share purchase plan (SPP), following the $6.3 billion placement
  • Last year, the company announced its plans to raise the money to buy Switzerland-based Vifor for $16.4 billion in cash
  • Under the SPP, investors grabbed CSL shares for $253.57 each, a two per cent discount to the five-day volume weighted average price
  • CEO and Managing Director Paul Perrault was pleased with the strong support for the purchase of Vifor Pharma from CSL’s shareholders
  • CSL last traded at $248.50 per share

CSL (CSL) has completed its $750 million share purchase plan (SPP), following its $6.3 billion placement.

Last year, the company announced its plans to raise the money to buy Switzerland-based Vifor for $16.4 billion in cash.

Under the SPP, investors grabbed CSL shares for $253.57 each, representing a two per cent discount to the five-day volume-weighted average price.

CSL saw the total of applications exceed the SPP target size, with valid applications totalling over $942.6 million.

The company then undertook a pro-rata scale-back of applications in-line with the scale-back principles set out in the SPP booklet.

“These principles were structured with shareholder fairness in mind and designed to deliver as close to pro-rata outcome as possible,” the company said.

CEO and Managing Director Paul Perrault was pleased with the strong support for the purchase of Vifor Pharma from CSL’s shareholders.

“On behalf of the Board, I wish to thank all shareholders who participated in the SPP. We look forward to delivering on the exciting growth opportunities underpinning the acquisition of Vifor Pharma,” he said.

Just before the market opens for the week, CSL last traded at $248.50 per share.

CSL by the numbers
More From The Market Herald
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…
Antisense Therapeutics (ASX:ANP) - MD and CEO, Mark Diamond

" Antisense Therapeutics (ASX:ANP) to present new data

Antisense Therapeutics (ASX:ANP) announces its new proteomics data will be presented in a virtual congress.